Are you Dr. Senzer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Department Of Radiation Oncology
Dallas, TX 75246Phone+1 214-370-1400Fax+1 214-370-1405
Summary
- Dr. Neil Senzer, MD is a radiation oncologist in Dallas, Texas. He is currently licensed to practice medicine in Texas. He is affiliated with Baylor University Medical Center and Medical City Dallas.
Education & Training
St Barnabas Medical CenterResidency, Radiation Oncology, 1982 - 1985
University of TennesseeFellowship, Pediatric Hematology/Oncology, 1976 - 1978
Johns Hopkins UniversityResidency, Pediatrics, 1971 - 1974
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1971
Certifications & Licensure
TX State Medical License 1985 - 2018- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
- American Board of Radiology Therapeutic Radiology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- 131-I-TM-601 Study in Adults With Solid Tumors Start of enrollment: 2006 Aug 01
- Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer Start of enrollment: 2006 Nov 01
- An Extension Study for Patients Previously Treated With ARQ 501 Start of enrollment: 2006 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncolog...Rodney P Rocconi, Bradley J Monk, Adam Walter, Thomas J Herzog, Evanthia Galanis
Gynecologic Oncology. 2023-02-01 - 8 citationsENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.Rodney P Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter
Communications Medicine. 2022-01-01 - 23 citationsGemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.Rodney P. Rocconi, Bradley J. Monk, Adam Walter, Thomas J. Herzog, Evanthia Galanis
Gynecologic Oncology. 2021-03-11
